Steer Clear of Viberzi in Patients Who Don't Have a Gallbladder

May 2017

FDA is now warning to avoid Viberzi (eluxadoline) in patients who don't have a gallbladder.

This is due to an increased risk of serious pancreatitis that can result in hospitalization or death in these patients.

You've likely seen ads promoting Viberzi for irritable bowel syndrome with diarrhea. It's an opioid agonist that works primarily in the gut at usual doses...similar to loperamide (Imodium A-D, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cholesterol Continue to Expect a Limited Role for PCSK9 Inhibitors
Pregnancy Watch for Oral Antibiotics to Avoid During Pregnancy
Oral Health Don't Use Antibiotic Prophylaxis Prior to Dental Procedures for Most Patients
HIV & AIDS Know What to Watch for With Complex Regimens in Hospitalized HIV Patients
Gastroenterology Steer Clear of Viberzi in Patients Who Don't Have a Gallbladder
Back Pain Don't Rely on Acetaminophen for Chronic Low Back Pain
Antithrombotics Consider Anticoagulants After Intracranial Hemorrhage in Some A Fib Patients
Overactive Bladder Put the Efficacy and Safety of Overactive Bladder Meds Into Perspective
Respiratory & Allergy Help Patients Know the Differences Among OTC Oral Antihistamines
Cardiology Don't Rely on Fish Oil Supplements to Reduce CV Risk
Rosacea Save Rhofade or Mirvaso for Rosacea Patients With Persistent Facial Redness

Steer Clear of Viberzi in Patients Who Don't Have a Gallbladder

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents